Aspirin for Stroke Prevention in Elderly Patients with Vascular Risk Factors: Japanese Primary Prevention Project

Stroke

Volumn 47, Issue 6, 2016, Pages 1605-1611

  Uchiyama, Shinichiro ^a   Ishizuka, Naoki ^b   Shimada, Kazuyuki ^c   Teramoto, Tamio ^d   Yamazaki, Tsutomu ^e   Oikawa, Shinichi ^f   Sugawara, Masahiro ^g   Ando, Katsuyuki ^h   Murata, Mitsuru ⁱ   Yokoyama, Kenji ^j   Minematsu, Kazuo ^k   Matsumoto, Masayasu ^l   Ikeda, Yasuo ^m  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Shin Oyama City Hospital   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^f Division of Pathology   (Japan)

^g Japan Physician's Association   (Japan)

^h Kitamura Neurosurgery Clinic   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

^j TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^k NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^l HIROSHIMA UNIVERSITY   (Japan)

^m WASEDA UNIVERSITY   (Japan)

more..

Author keywords

aspirin; diabetes mellitus; intracranial hemorrhage; risk factor; stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FATALITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TRANSIENT ISCHEMIC ATTACK; CHEMICALLY INDUCED; COMORBIDITY; DYSLIPIDEMIAS; INTRACRANIAL HEMORRHAGES; JAPAN; MIDDLE AGED; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INTRACRANIAL HEMORRHAGES; JAPAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK FACTORS; STROKE;

EID: 84966705393     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.012461     Document Type: Article

References (30)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354:1457-1463. doi: 10.1016/S0140-6736(99)04407-4.
3. Reny JL, Berdagué P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al; Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation. 2012;125:3201-3210. doi: 10.1161/CIRCULATIONAHA.111.085464.
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
5. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95.
6. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304. doi: 10.1056/NEJMoa050613.
7. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
8. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1:e259-e281.
9. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118:2702-2709. doi: 10.1161/CIRCULATIONAHA.108.790048.
10. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510-2520. doi: 10.1001/jama.2014.15690.
11. Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J. 2010;159:361-369.e4. doi: 10.1016/j. ahj.2009.11.030.
12. ClinicalTrials.gov Web site. A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE). http://clinicaltrials.gov/ct2/show/NCT00501059?term=ARRIVE+aspirin&rank=1. Accessed March 15, 2016.
13. ClinicalTrials.gov Web site. ASCEND: A Study of Cardiovascular Events in Diabetes. http://clinicaltrials.gov/ct2/show/NCT00135226?te rm=ascend+aspirin&rank=1. Accessed March 15, 2016.
14. ClinicalTrials.gov Web site. Aspirin in Reducing Events in the Elderly (ASPREE). http://clinicaltrials.gov/ct2/show/NCT01038583. Accessed March 15, 2016.
15. ISRCTN Register Web site. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes. http://www.isrctn. com/ISRCTN48110081. Accessed March 15, 2016.
16. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383. doi: 10.1056/NEJMra052717.
17. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391.
18. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
19. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266-275. doi: 10.7326/M14-1281.
20. World Health Organization. World Health Statistics Annual 1967-2012. Geneva, Switzerland: World Health Organization; 2012.
21. Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009). Circulation. 2013;128:1198-1205. doi: 10.1161/CIRCULATIONAHA.113.002424.
22. Arima H, Tanizaki Y, Yonemoto K, Doi Y, Ninomiya T, Hata J, et al. Impact of blood pressure levels on different types of stroke: the Hisayama study. J Hypertens. 2009;27:2437-2443. doi: 10.1097/HJH.0b013e328330e882.
23. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060-2065. doi: 10.1161/01.STR.0000080678.09344.8D.
24. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al; INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123. doi: 10.1016/S0140-6736(10)60834-3.
25. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-1911. doi: 10.1016/S0140-6736(14)60685-1.
26. SPS Study Group. Blood pressure targets in patients with recent lacunar stroke: the SPS3 randomized trial. Lancet. 2013;382:507-515.
27. Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, et al; Bleeding With Antithrombotic Therapy (BAT) Study Group. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding With Antithrombotic Therapy (BAT) Study. Stroke. 2010;41:1440-1444. doi: 10.1161/STROKEAHA.110.580506.
28. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253-390. doi: 10.1038/hr.2014.20.
29. Stroke Guideline Committee of the Japan Stroke Society. Japanese Guidelines for the Management of Stroke. Tokyo, Japan: Kyowa Kikaku; 2015.
30. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024.